-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 19, Connoya announced that the company's core product Claudin 18.2 antibody-conjugated drug CMG901 biological product license application was accepted by the US Food and Drug Administration and was granted priority review. It is intended to be used for second-line and subsequent treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with an expression ratio of at least 25% of tumor cells, covering about 60% of patients with gastric cancer/GEJ cancer. CMG901 is the first CLDN18.2 ADC to submit a new drug marketing application globally. The target review completion date for this BLA is expected to be in the second quarter of 2027.
Share
Listen to the news
On November 19, Connoya announced that the company's core product Claudin 18.2 antibody-conjugated drug CMG901 biological product license application was accepted by the US Food and Drug Administration and was granted priority review. It is intended to be used for second-line and subsequent treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with an expression ratio of at least 25% of tumor cells, covering about 60% of patients with gastric cancer/GEJ cancer. CMG901 is the first CLDN18.2 ADC to submit a new drug marketing application globally. The target review completion date for this BLA is expected to be in the second quarter of 2027.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending